Innovative drug development ushers in a new model of how fast and good province

Siono Biomedicine (Hangzhou) Co., Ltd., a wholly owned subsidiary of TheO22Pharma, has received a global license for the clinical Phase III anti-tumor drug Enzataurin from leading U.S Lilly Pharmaceuticals Under the terms of the agreement, Soyuan Biopharmaceuticals will have all rights to the global development, production and sale of the drug, including all intellectual property rights and other related rights and data it is learned that this is the first time that China's pharmaceutical companies from the international pharmaceutical companies to obtain clinical phase III innovation drug global authorization, the essence of which is that the international pharmaceutical companies to the use of biomarkers to develop innovative drug model recognition It means that China's pharmaceutical enterprises have a "how fast and good province" innovative drug development new model It is understood that the promotion of this Lilly and Soyuan cooperation, is the original biomarker platform technology and personalized medicine experience This is also the technical support of Soyuan Biopharmaceuticals to position itself as a "personalized innovative pharmaceutical company with a unique business model" because of the innovation drug research and development has a long time (more than 10 years), the cost (more than 1 billion U.S.), high risk and so on, has been the majority of pharmaceutical companies retreat, and the vast majority of the global market innovation drugs are monopolized by European and American pharmaceutical companies, because innovative drugs have a much higher market return than generic drugs " agreement with Lilly marks a new milestone in the development of soyuan Soyuan Chairman Dr Xiang Ming said that this cooperation, means that Soyuan can use its own technological advantages, for Chinese pharmaceutical enterprises to develop a class of innovative drugs with international advanced level to explore a new path of how fast and good province "The high-quality clinical data and a large number of clinical samples from Lilly for Enzataurin's research and development contribute to the development of biomarkers," said Dr Rowan, General Manager of The reverse all-gene scanning platform of Soyuan is more mature, using this platform to discover biomarkers in a short time, combined with The data and data already available at Lilly, we hope to launch a new personalized treatment OfDLBCL clinical trial to verify the efficacy of our biomarkers and Enzaurin in the selected patients "Responsible Editor: xcp